Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Friday's Featured News Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostWritten by Chris Markoch. First Published: 2/5/2026. 
Summary - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped lift the Dow Jones Industrial Average the day after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion. On the bottom line, Pfizer reported adjusted earnings per share (EPS) of $0.69, beating estimates of $0.57. A highlight of the report was Pfizer's announcement of positive topline results from the Phase 2b study for its lead GLP-1 candidate. The largest gold buyer in the world is expected to release a revolutionary way to invest in gold in 2026, potentially changing how everyday Americans save their wealth with a click of a button. Gold would need to climb another $4,500 for you to double your money at current prices. But one gold stock trading around $1.60 only needs to rise another $1.60 for you to double. That's the conservative estimate of what could happen when this new investment method becomes available to the public. Get the details on this opportunity before the 2026 launch. PFE stock closed up 4% on Feb. 4 as analysts and investors digested the report. The bullish thesis is that while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside is likely to come from its expanding oncology pipeline and its accelerating use of artificial intelligence across R&D. That narrative starts with the company's push into obesity, where it reported a notable clinical update alongside the quarter. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is expanding rapidly. Data shows the global GLP-1 market will grow from $62.2 billion in 2025 to $157 billion by 2035. That represents a compound annual growth rate (CAGR) of 9.7% and helps explain why billions of dollars are flowing into the industry from companies trying to carve out market share. For Pfizer, the opportunity centers on its lead GLP-1 candidate, MET-097i. The company announced results from its Phase 2b VESPER-3 study, which met its primary endpoint and showed statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also noted that patients continued to lose weight after transitioning from weekly to monthly dosing, with no plateau observed by the end of the 28 weeks. The Growth Driver Investors May Be Missing Immediately after the report, conventional wisdom pointed to the positive clinical results as the main reason for the stock's gain. That may be true, but investors should recognize the likely short-term nature of that boost. While Pfizer's GLP-1 program shows promise, it will take time for sales to meaningfully affect the company's financials. And the GLP-1 market is becoming more competitive — as Eli Lilly & Co. (NYSE: LLY) demonstrated in its own earnings, the largest players aren't going to cede leadership in obesity therapeutics easily. There are, however, other reasons to be bullish on PFE — notably its oncology portfolio. Business Research Insights values the global oncology drugs market at roughly $264.92 billion in 2026 and projects it will rise to $648.08 billion by 2035, reflecting a CAGR of about 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer had roughly 60 candidates in its portfolio, which translates to multiple opportunities to capture market share. The portfolio was substantially enhanced by its acquisition of Seagen in 2023. Pfizer's pipeline combines late-stage candidates such as vepdegestrant, a next-generation targeted protein degrader (PROTAC), and atirmociclib, a selective CDK4 inhibitor, which are being tested in later-stage trials for ER+/HER2- metastatic breast cancer. Other late-stage candidates include: - Sigvotatug vedotin, an antibody-drug conjugate (ADC) in Phase 3 testing (e.g., Be6A LUNG-01) against metastatic non-small cell lung cancer, leveraging Pfizer's Seagen-acquired ADC expertise.
- Sasanlimab, being developed for bladder cancer, and a bispecific PD-1xVEGF agent (PF-4404) that is being studied in combination with Padcev to treat urothelial cancer — all potential blockbusters as oncology demand grows.
Pfizer could be bringing multiple drugs to market over the next five to 10 years. That potential is amplified by the company's commitment to artificial intelligence (AI), which is becoming essential across the biopharmaceutical sector. Pfizer integrates AI across R&D through partnerships like Boltz for biomolecular modeling, XtalPi for molecular design, and Data4Cure for oncology data analytics, accelerating target identification with tools such as OncoScout. Internally, platforms like "Charlie" handle data mining, predictions, and content generation, while collaborations with NVIDIA (NASDAQ: NVDA) support discovery and manufacturing optimization. These AI efforts helped enable the rapid development of Paxlovid and support multiple 2026 catalysts in oncology and obesity. Pfizer is targeting $1.2 billion in savings by 2027 through efficiency gains. Industry-wide, AI is projected to boost productivity by 35% to 45% by improving preclinical decisions and trial design, making it a core competitive advantage rather than optional hype. Pfizer's early and broad adoption of AI tools positions the company to benefit over the medium and long term, which should be attractive to investors beyond the immediate GLP-1 excitement.
| 
